⌘K
Loading ticker…
Avalo Therapeutics, Inc. Common Stock · Healthcare · Pharmaceutical Products
As of 2026-06-26, Avalo Therapeutics, Inc. Common Stock (AVTX) has a 3-month relative strength percentile of 81 within the TickerStance CS+ADRC universe (~5,000 tickers). Its Power rating (absolute 1–99) is 74. The current market Stance is 47 (Neutral). Sector: Healthcare. Average daily range 7.3%, relative volume 5.00×. TickerStance reports observed regime conditions across the full CS+ADRC universe; band assignment reflects current breadth, momentum, and macro inputs computed at the daily close. Percentile ranks run from 1 (weakest) to 99 (strongest) relative to all universe members on the same date.
Diluted EPS, last 8 quarters. Loss makers are judged by progress toward breakeven.
Relative strength across horizons plus the leadership score.
Accumulation rating, relative volume, U/D ratio, breakout-day proof.
3m RS is 81, Market Stance is mixed at 47, A/D rating B
YoY sales growth, last 8 quarters. Sales must back the earnings story.
TTM operating margin. Expansion = real operating leverage.
YoY common shares outstanding. Down = buyback tailwind. Up > 2% = dilution flag.
Reported figures from SEC filings. No analyst estimates or forward guidance.
Daily range, ATR, beta, and the math for a 1-ADR stop.
Strong relative strength, but attention is quiet relative to this name’s own recent norm. Academic work links low public attention to better forward returns on average — context to weigh, not a forecast.
Measures how unusual this name’s public attention is against its own 90-day history — a surprise reading, not a ranking of how watched it is versus other stocks. Intel, not a signal.
News
Related searches
AVTX is held by 2 ETFs as of Mar 2026. Top owner: VTI at 0.00% weight, $8M notional.
Top 2 by value, from SEC N-PORT-P filings dated Mar 2026.
| ETF | Weight | Value |
|---|---|---|
| VTIVanguard Total Stock Market ETF | 0.00% | $8M |
| VXFVanguard Extended Market ETF | 0.00% | $2M |
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | AVTX Jan avg: -18.52% median: -19.26% win: 25% σ: 25.50% n: 4 2022-04-12 → 2026-05-29 | AVTX Feb avg: -9.66% median: -9.17% win: 25% σ: 21.46% n: 4 2022-04-12 → 2026-05-29 | AVTX Mar avg: 89.38% median: -2.56% win: 50% σ: 203.21% n: 4 2022-04-12 → 2026-05-29 | AVTX Apr avg: -7.68% median: -21.29% win: 20% σ: 42.83% n: 5 2022-04-12 → 2026-05-29 | AVTX May avg: -9.22% median: -12.34% win: 20% σ: 19.28% n: 5 2022-04-12 → 2026-05-29 | AVTX Jun avg: -4.33% median: 15.73% win: 75% σ: 57.07% n: 4 2022-04-12 → 2026-05-29 (current) | AVTX Jul avg: -8.58% median: -24.37% win: 25% σ: 47.15% n: 4 2022-04-12 → 2026-05-29 | AVTX Aug avg: -9.70% median: -10.37% win: 50% σ: 40.58% n: 4 2022-04-12 → 2026-05-29 | AVTX Sep avg: 15.78% median: 28.21% win: 75% σ: 31.46% n: 4 2022-04-12 → 2026-05-29 | AVTX Oct avg: 37.56% median: 39.40% win: 75% σ: 36.86% n: 4 2022-04-12 → 2026-05-29 | AVTX Nov avg: -16.57% median: -17.76% win: 25% σ: 18.48% n: 4 2022-04-12 → 2026-05-29 | AVTX Dec avg: -20.04% median: -14.99% win: 0% σ: 18.80% n: 4 2022-04-12 → 2026-05-29 |